[CAS NO. 1922098-69-8] CCG-222740
Please click "REQUEST A QUOTE" button if you need other sizes or
custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis,
please:
PRODUCTS SPECIFICATIONS [1922098-69-8]
Catalog
SLK-S6673
Brand
Selleck
CAS
1922098-69-8
DESCRIPTION [1922098-69-8]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 444.86 |
| Molecular Formula | C23H19ClF2N2O3 |
| SMILES | O=C(C1CN(C(C2=CC=CC(C3=CC=CO3)=C2)=O)CC(F)(F)C1)NC4=CC=C(Cl)C=C4 |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2479 mL | 11.2395 mL | 22.4790 mL |
| 5 mM | 0.4496 mL | 2.2479 mL | 4.4958 mL |
| 10 mM | 0.2248 mL | 1.1239 mL | 2.2479 mL |
| 50 mM | 0.0450 mL | 0.2248 mL | 0.4496 mL |
Description
CCG-222740 is a inhibitor. CCG-222740 decreases the activation of stellate cells in vitro and in vivo, by reducing the levels of expression.
In vitro
CCG-222740 increases the protein levels of p27 and decreased cyclin D1. CCG-222740 treatment decreased cell viability of CAFs, with an IC50 of~10 μM, as measured by the MTT assay. In pancreatic cancer, CAFs are one of the main producers of matrix proteins, including several collagen isoforms. The Rho/MRTF pathway inhibitor CCG-222740 decreases the levels of collagens I, 2a and IV, as well as α-SMA in the CAFsIn cancer cells. CCG-222740 treatment leads to the exclusion of MRTF from the nucleus. .
Powered by Arctom Copyright © 2025 Arctom.
All rights reserved.